Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depression, Treatment Resistant Clear all
Suspended Not applicable Interventional

Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias

NCT04202770
View directory record Official record
Conditions
Refractory Depression, Anxiety Disorders, Neurodegenerative Diseases
Interventions
Exosomes
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 1 Interventional

Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder

NCT04226352
View directory record Official record
Conditions
MDD, Treatment Resistant Depression, Smoking Cessation, Smoking
Interventions
Dextromethorphan
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional

Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression

NCT01431001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
Device
Lead sponsor
Cervel Neurotech, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional Results available

Treatment Resistant Depression (Pilot)

NCT01179009
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Ketamine, Clonidine, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 23, 2026, 7:08 PM EDT
Active, not recruiting Not applicable Interventional

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

NCT06670040
View directory record Official record
Conditions
ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions
Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 26 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Investigational TMS Treatment for Depression

NCT03175887
View directory record Official record
Conditions
Depression, Treatment Resistant Depression
Interventions
TMS
Device
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 23, 2026, 7:08 PM EDT
Active, not recruiting No phase listed Observational

Open Label Optimization Study

NCT05819021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAINT® Neuromodulation System (NMS)
Device
Lead sponsor
Magnus Medical
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Costa Mesa, California • Los Angeles, California • Sunnyvale, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine Nasal Spray
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
51
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 23, 2026, 7:08 PM EDT
Not yet recruiting Phase 4 Interventional

Biomarker-Guided Antidepressant Selection

NCT07680140
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine, fMRI
Interventions
TMS, Ketamine
Device · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Terminated Phase 1 Interventional

Adaptive tDCS for Treatment-Resistant MDD

NCT02942368
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
tDCS
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

A Study in Relapse Prevention of Treatment-Resistant Depression

NCT00958568
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Olanzapine and Fluoxetine combination (OFC), Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
36
States / cities
Pasadena, California • Sherman Oaks, California • Wildomar, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

NCT02356107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-hydroxytryptophan and Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional

Exercise in Treatment Resistant Depression (TRD): A Feasibility Study

NCT01383811
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Moderate Intensity Aerobic Exercise, Wait-list
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional Results available

Insulin Resistance in Patients With Mood Disorder

NCT00242619
View directory record Official record
Conditions
Depression, Bipolar Disorder, Insulin Resistance
Interventions
rosiglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Jul 23, 2026, 7:08 PM EDT
Recruiting Phase 1 Interventional

Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

NCT03522545
View directory record Official record
Conditions
Treatment-resistant Bipolar Depression
Interventions
Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs), Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional Results available

rTMS in Treatment Resistant Depression

NCT02080507
View directory record Official record
Conditions
Depression
Interventions
Active Neuronetics rTMS stimulator, Inactive Neuronetics rTMS stimulator
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 4 Interventional Results available

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

NCT02977299
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Active, not recruiting Not applicable Interventional

Compressed Intermittent Theta Burst Stimulation

NCT04684706
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
intermittent Theta Burst Stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT04739865
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Treatment Resistant Geriatric Depression in Primary Care

NCT01392287
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 23, 2026, 7:08 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression

NCT06002204
View directory record Official record
Conditions
Depression, Treatment Resistant Depression, Mood Disorders, Bipolar Disorder, Mental Disorders, Bipolar and Related Disorders
Interventions
Observational Study
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years and older
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2035
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Placebo Midazolam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Nuedexta in Treatment-Resistant Major Depression

NCT01882829
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant
Interventions
dextromethorphan/quinidine
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Jul 23, 2026, 7:08 PM EDT